Baricitinib for active alopecia areata with recent hair loss
Treatments studied
Part of Skin clinical trials.
This study tests a pill called baricitinib for people with active alopecia areata that started within the last 3 months. Baricitinib is a type of medication called a JAK inhibitor, which can help calm the immune system and stop hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have alopecia areata (not another cause of hair loss) that started within the last 3 months and is currently active, meaning at least 30% of your scalp is affected and hair falls out easily when gently pulled.
- You have not taken a JAK inhibitor (like baricitinib) before for hair loss that didn't work.
- You do not have an active infection (like tuberculosis, hepatitis B or C, or HIV) or have had shingles in the last 12 weeks.
- You have not used steroid injections in your scalp for alopecia areata in the last 4 weeks, and you are not currently using strong steroids or other immune-suppressing medications for other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests whether a new drug called LY4005130 can help regrow hair in adults with severe alopecia areata (an autoimmune condition causing patchy or widespread hair loss). The trial is looking for people who have lost a significant amount of hair and haven't seen it grow back on its own for at least 6 months.
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This study tests an experimental oral tablet for severe alopecia areata, a condition that causes patches of hair to fall out. The goal is to see if it can help regrow hair safely. You may be able to join if you have this type of hair loss and meet the health requirements.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.